Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome

• Sponsor: Woman's Health University Hospital, Egypt (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT02644304
• Collaborator: (none)
• Enrollment: 88
• Location: 1
• Arms: 2
• Duration (Months): 19.1
• Patients Per Site Per Month: 4.6

Study Details

Study Description

Brief Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive aged women and affects approximately 5-12 % of the female population.

In 2003 in Rotterdam , Rotterdam diagnostic criteria were redefined PCOS as affected individuals must have two out of the following three criteria:

1. Oligo- and/or anovulation, (ovulation occurs less than once every 35 days).

2. Hyperandrogenism, clinical signs include hirsutism, acne, alopecia, and frank virilization, while chemical indicators include raised concentrations of total testosterone and androstenedione , and elevated free androgen index.

3. Polycystic ovaries on sonographic examination, presence of 12 or more follicles in either ovary measuring 2-9 mm in diameter, increased ovarian volume more than 10 cm3 and/or increase in stromal echogenicity. Clearly, according to the Rotterdam diagnostic criteria, the majority of women with PCOS can be diagnosed without the need of laboratory examinations.

Clomiphene citrate (CC) is still the first-line medication for the induction of ovulation. It is an anti-estrogenic compound made up of two isomers, enclomiphene and zuclomiphene; the latter being the more potent of the two. It is a non-steroidal compound closely resembling estrogen. CC acts by blocking estrogen receptors, particularly in the hypothalamus, thereby signaling a lack of circulating estrogens and inducing a change in the pulsatile release of gonadotrophin-releasing hormone (GnRH). This induces release of follicle stimulating hormone from the anterior pituitary and is often enough to set the cycle of events leading to ovulation into motion.

Cabergoline, ergot-derived dopamine agonists with a very long half life, is an effective prolactin suppressor. Cabergoline oral administration contains a weekly dose of 0.5 - 3 mg, which could be increased, if needed, to twice a week. This medicine has slight dopamine agonistic side effects, headache being the most common one. Treatment in the very beginning should start with a partial dose (half a pill) at bedtime with a small amount of food. Low incidence of side effects and its weekly dose has made Cabergoline a choice drug for treatment of related diseases.

Condition or Disease	Intervention/Treatment	Phase
Female Reproductive Problem	Drug: Clomiphene citrate; Drug: Cabergoline; Other: Placebo	Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 88 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility
• Study Start Date: May 1, 2015
• Anticipated Primary Completion Date: Oct 1, 2016
• Anticipated Study Completion Date: Dec 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Clomiphene citrate plus cabergoline This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)	Drug: Clomiphene citrate; 50 mg tablet twice daily from the second day of menses to the sixth day; Drug: Cabergoline; Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
Active Comparator: Clomiphene citrate plus placebo This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)	Drug: Clomiphene citrate; 50 mg tablet twice daily from the second day of menses to the sixth day; Other: Placebo; placebo(half tablet) every 3 days (4 doses).

Outcome Measures

Primary Outcome Measures

1. Size of mature follicles (mm). [1 year]

Secondary Outcome Measures

1. Number of pregnancy [1 year]

2. Number of mature follicles (mm) [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 40 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 2 or more of PCOS signs according to Rotterdam diagnostic criteria (2003).-

• Primary or secondary infertility.-

• Absence of galactorrhoea

• Normal serum prolactin or slightly elevated (up to 50 ng/dl)

• Normal hysterosalpingography

• Normal spermogram

Exclusion Criteria:

• Women on other line of treatment as aromatase inhibitors, gonadotrophins, or tamoxifen.

• Known hypersensitivity for Clomiphene citrate or cabergoline.

• Other factors of infertility as tubal factor, uterine factor or male factor.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Assiut university	Assiut		Egypt	71111

Sponsors and Collaborators

• Woman's Health University Hospital, Egypt

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Kamal Mohamed Zahran, Dr, Woman's Health University Hospital, Egypt
• ClinicalTrials.gov Identifier: NCT02644304
• Other Study ID Numbers: CC in PCOS
• First Posted: Dec 31, 2015
• Last Update Posted: Jun 29, 2016
• Last Verified: Jun 1, 2016

• Additional relevant MeSH terms: Polycystic Ovary Syndrome; Cabergoline; Clomiphene; Enclomiphene; Zuclomiphene

Study Results

No Results Posted as of Jun 29, 2016